Trials / Unknown
UnknownNCT04450732
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors
A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- GeneQuantum Healthcare (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase I Dose Finding Study for GQ1001 in Patients with HER2-Positive Advanced Solid Tumors
Conditions
- HER2-positive Breast Cancer
- HER2-positive Biliary Tract Cancer
- HER2-Positive Salivary Gland Carcinomas
- HER2-Positive Advanced Solid Tumor
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GQ1001 | anti-HER2 antibody drug conjugate |
Timeline
- Start date
- 2020-07-07
- Primary completion
- 2024-03-01
- Completion
- 2024-05-01
- First posted
- 2020-06-29
- Last updated
- 2023-12-05
Locations
24 sites across 3 countries: United States, Australia, China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04450732. Inclusion in this directory is not an endorsement.